ZEO SCIENTIFIX (ZEOX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 27, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-KT for Q4 FY2026, filed Oct 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ZEOX SEC filings page.
ZEO SCIENTIFIX INC (ZEOX) reported $5.2M in revenue for fiscal year 2025, up 12.5% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Zeo ScientifiX’s high-margin sales still cannot cover overhead, leaving persistent losses, negative free cash flow, and liabilities above assets.
Cash consumption is smaller than the accounting loss: FY2025 reported a net loss of$5.5M but operating cash flow of-$718K , so earnings do not translate one-for-one into current cash use. Yet free cash flow was-$741K while capital expenditures were only$23K , indicating the shortfall is primarily operating rather than reinvestment-driven.
The company’s gross margin was 82.1%, but selling, general and administrative costs consumed
The balance sheet remains liability-heavy and short-term constrained: liabilities equaled
Financial Health Signals
ZEO SCIENTIFIX INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
ZEO SCIENTIFIX INC scores -69.61, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $67.7M against total assets of $1.5M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
ZEO SCIENTIFIX INC passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
ZEO SCIENTIFIX INC reported a net loss of $5.5M while operations used $718K of cash. With neither figure positive, the ratio between the two carries no quality signal.
ZEO SCIENTIFIX INC reported an operating loss of $5.4M against $98K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q4 2026.
Cash & Balance Sheet
ZEO SCIENTIFIX INC generated $226K in free cash flow in Q4 2026, representing cash available after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
ZEO SCIENTIFIX INC held $2.3M in cash as of Q4 2026; no long-term debt figure is on record for that period.
Not reported for Q4 2026.
Margins & Returns
None of these metrics is reported for Q4 2026.
Capital Allocation
ZEO SCIENTIFIX INC reported no capital expenditure in Q4 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Not reported for Q4 2026.
Not reported for Q4 2026.
ZEOX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-KT | Q2'2610-Q | Q1'2610-Q | Q4'2510-KT | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-KT |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $2.6M+124.6% | $1.4M+32.7% | $1.7M+33.0% | $1.3M+19.7% | $1.1M+1.6% | $1.1M-5.5% | $1.2M-12.5% |
| Cost of Revenue | N/A | $526K+105.5% | $281K+47.1% | $256K+13.8% | $228K+29.5% | $256K-9.9% | $191K+20.1% | $225K+67.9% |
| Gross Profit | N/A | $2.1M+130.1% | $1.2M+29.6% | $1.4M+37.2% | $1.1M+17.8% | $893K+5.4% | $899K-9.6% | $1.0M-20.9% |
| R&D Expenses | N/A | $31K-26.2% | $19K+216.7% | N/A | N/A | $42K+740.0% | $6K-77.8% | $57K+328.6% |
| SG&A Expenses | N/A | $2.8M+18.9% | $2.1M-3.1% | $2.1M-21.7% | $3.1M+51.2% | $2.4M-2.1% | $2.2M+0.9% | $2.7M+6.8% |
| Operating Income | N/A | -$512Kn/m | -$878Kn/m | -$668Kn/m | -$2.1Mn/m | -$1.4Mn/m | -$1.3Mn/m | -$1.4Mn/m |
| EBITDA | N/A | -$493Kn/m | -$859Kn/m | -$648Kn/m | -$2.1Mn/m | -$1.4Mn/m | -$1.2Mn/m | -$1.4Mn/m |
| Interest Expense | N/A | $11K-47.6% | $10K-54.5% | $32K+45.5% | $23K0.0% | $21K+5.0% | $22K-18.5% | $22K-75.3% |
| Net Income | N/A | -$145Kn/m | -$852Kn/m | -$815Kn/m | -$2.1Mn/m | -$1.4Mn/m | -$1.2Mn/m | -$1.3Mn/m |
| EPS (Basic) | N/A | -$0.02n/m | -$0.12n/m | -$0.12n/m | -$0.32n/m | -$0.22n/m | -$0.20n/m | -$0.19n/m |
| EPS (Diluted) | N/A | -$0.02n/m | -$0.12n/m | -$0.12n/m | -$0.32n/m | -$0.22n/m | -$0.20n/m | -$0.19n/m |
| Diluted Shares (Avg) | N/A | 8M+22.3% | 7M+10.7% | N/A | 6M+2.3% | 6M+2.8% | 6M+2.5% | N/A |
Not reported in any period shown, so not listed: Income Tax.
ZEOX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-KT | Q2'2610-Q | Q1'2610-Q | Q4'2510-KT | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-KT |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $4.1M+168.4% | $3.9M+170.8% | $2.6M+65.9% | $1.5M-7.1% | $1.7M-25.6% | $1.4M-25.7% | $1.6M-36.3% | $1.6M-40.9% |
| Current Assets | $3.5M+263.8% | $3.3M+277.6% | $2.0M+84.1% | $958K-17.8% | $1.1M-38.4% | $865K-39.0% | $1.1M-42.4% | $1.2M-47.1% |
| Cash & Equivalents | $2.3M+924.9% | $1.8M+240.6% | $1.0M+43.1% | $221K-66.4% | $314K-71.6% | $542K-27.3% | $720K-38.6% | $657K-62.6% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Inventory | $796K+88.2% | $686K+191.9% | $502K+104.9% | $423K+82.3% | $258K+3.2% | $235K-13.6% | $245K-22.5% | $232K-25.2% |
| Accounts Receivable | $245K+600.0% | $276K+2409.1% | $63K+950.0% | $35K-82.0% | N/A | $11K-81.7% | $6K-92.2% | $194K+977.8% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $3.5M+17.9% | $3.2M-10.2% | $3.0M-12.0% | $3.0M-10.5% | $4.0M+8.9% | $3.5M-2.7% | $3.4M-14.8% | $3.3M-18.1% |
| Current Liabilities | $3.4M+19.0% | $3.1M-9.9% | $2.9M-13.8% | $2.9M-12.6% | $3.9M+6.6% | $3.5M-4.6% | $3.3M-14.6% | $3.3M-18.0% |
| Non-Current Liabilities | $59K-23.4% | $63K-23.2% | $68K+1033.3% | $77K+862.5% | $91K+911.1% | $82K+645.5% | $6K-64.7% | $8K-38.5% |
| Total Equity | $583Kn/m | $712Kn/m | -$383Kn/m | -$1.4Mn/m | -$2.3Mn/m | -$2.1Mn/m | -$1.8Mn/m | -$1.7Mn/m |
| Retained Earnings | -$72.8Mn/m | -$68.7Mn/m | -$68.6Mn/m | -$67.7Mn/m | -$66.9Mn/m | -$64.8Mn/m | -$63.5Mn/m | -$62.2Mn/m |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
ZEOX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-KT | Q2'2610-Q | Q1'2610-Q | Q4'2510-KT | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-KT |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $226Kn/m | -$138Kn/m | -$471K-824.6% | -$383Kn/m | -$257Kn/m | -$143Kn/m | $65Kn/m | -$366K-265.6% |
| Depreciation & Amortization | $14K-30.0% | $19K+18.8% | $19K+5.6% | $20K+11.1% | $19K+5.6% | $16K-15.8% | $18K-5.3% | $18K+12.5% |
| Stock-Based Compensation | N/A | $590K-46.2% | $592K-45.7% | N/A | N/A | $1.1M | $1.1M+41.1% | N/A |
| Capital Expenditures | $0n/m | $64K | $14K | $0 | N/A | N/A | N/A | N/A |
| Free Cash Flow | $226Kn/m | -$202K | -$485K | -$383K | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $0n/m | $312K | -$14K | $0n/m | N/A | N/A | N/A | $0-100.0% |
| Financing Cash Flow | $193K-33.4% | $642Kn/m | $1.3Mn/m | $290Kn/m | $52K-89.6% | -$35Kn/m | -$2Kn/m | -$82K-149.1% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
ZEOX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-KT | Q2'2610-Q | Q1'2610-Q | Q4'2510-KT | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-KT |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | 79.6%+1.9pp | 80.6%-1.9pp | 84.5%+2.6pp | 82.5%-1.3pp | 77.7%+2.8pp | 82.5%-3.7pp | 81.9%-8.7pp |
| Operating Margin | N/A | -19.8% | -60.7% | -40.4% | -158.6% | -121.3% | -115.0% | -114.5% |
| Net Margin | N/A | -5.6% | -58.9% | -49.3% | -158.7% | -121.1% | -114.0% | -100.8% |
| Return on Equity | N/A | -20.4% | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | -3.7%+93.2pp | -33.1%+47.0pp | -53.4%+23.0pp | -125.4%-79.8pp | -96.9%-24.5pp | -80.2%-37.4pp | -76.3%-37.1pp |
| Current Ratio | 1.02+0.7x | 1.05+0.8x | 0.70+0.4x | 0.330.0x | 0.27-0.2x | 0.25-0.1x | 0.33-0.2x | 0.35-0.2x |
| Liabilities-to-Equity | 5.97 | 4.46 | N/A | N/A | N/A | N/A | N/A | N/A |
| Asset Turnover | N/A | 0.66-0.1x | 0.56-0.1x | 1.08+0.3x | 0.79+0.3x | 0.80+0.2x | 0.70+0.2x | 0.76+0.2x |
| FCF Margin | N/A | -7.8% | -33.5% | -23.2% | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Note: Shareholder equity is negative (-$1.4M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.33), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| ZEO SCIENTIFIX INC ZEOX | FY2025 | $5.2M | -$5.5M | N/A | $11.0M | — |
| BETTERLIFE PHARMA INC BETRF | FY2025 | N/A | N/A | N/A | $101.2M | — |
Where ZEO SCIENTIFIX INC Ranks
Frequently Asked Questions
What is ZEO SCIENTIFIX INC's annual revenue?
ZEO SCIENTIFIX INC (ZEOX) reported $5.2M in total revenue for fiscal year 2025. This represents a 12.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is ZEO SCIENTIFIX INC's revenue growing?
ZEO SCIENTIFIX INC (ZEOX) revenue grew by 12.5% year-over-year, from $4.6M to $5.2M in fiscal year 2025.
Is ZEO SCIENTIFIX INC profitable?
No, ZEO SCIENTIFIX INC (ZEOX) reported a net loss of $5.5M in fiscal year 2025.
What is ZEO SCIENTIFIX INC's EBITDA?
ZEO SCIENTIFIX INC (ZEOX) had EBITDA of -$5.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is ZEO SCIENTIFIX INC's gross margin?
ZEO SCIENTIFIX INC (ZEOX) had a gross margin of 82.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is ZEO SCIENTIFIX INC's free cash flow?
ZEO SCIENTIFIX INC (ZEOX) recorded an outflow of $741K in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is ZEO SCIENTIFIX INC's operating cash flow?
ZEO SCIENTIFIX INC (ZEOX) recorded an outflow of $718K in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are ZEO SCIENTIFIX INC's total assets?
ZEO SCIENTIFIX INC (ZEOX) had $1.5M in total assets as of fiscal year 2025, including both current and long-term assets.
What are ZEO SCIENTIFIX INC's capital expenditures?
ZEO SCIENTIFIX INC (ZEOX) invested $23K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does ZEO SCIENTIFIX INC spend on research and development?
ZEO SCIENTIFIX INC (ZEOX) invested $100K in research and development during fiscal year 2025.
What is ZEO SCIENTIFIX INC's current ratio?
ZEO SCIENTIFIX INC (ZEOX) had a current ratio of 0.33 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is ZEO SCIENTIFIX INC's return on assets (ROA)?
ZEO SCIENTIFIX INC (ZEOX) had a return on assets of -361.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is ZEO SCIENTIFIX INC's P/E ratio?
ZEO SCIENTIFIX INC (ZEOX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $11.0M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is ZEO SCIENTIFIX INC's price-to-sales ratio?
ZEO SCIENTIFIX INC (ZEOX) trades at 2.1x sales, its market capitalization divided by $5.2M revenue, FY2025. The market capitalization is $11.0M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does ZEO SCIENTIFIX INC's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, ZEO SCIENTIFIX INC (ZEOX) held $221K in cash, cash equivalents and investments, and reported an operating cash outflow of $718K over that year. Dividing the one by the other, the reported balance equals about 4 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is ZEO SCIENTIFIX INC's debt-to-equity ratio negative or not reported?
ZEO SCIENTIFIX INC (ZEOX) has negative shareholder equity of -$1.4M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is ZEO SCIENTIFIX INC's Altman Z-Score?
ZEO SCIENTIFIX INC (ZEOX) has an Altman Z-Score of -69.61, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is ZEO SCIENTIFIX INC's Piotroski F-Score?
ZEO SCIENTIFIX INC (ZEOX) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are ZEO SCIENTIFIX INC's earnings high quality?
ZEO SCIENTIFIX INC (ZEOX) reported a net loss of $5.5M while operations used $718K of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can ZEO SCIENTIFIX INC cover its interest payments?
ZEO SCIENTIFIX INC (ZEOX) reported an operating loss of $5.4M against $98K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.